Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Emeriti Pharma AB
AB
In liquidation
Org 5569727216
Other research and experimental development on natural sciences and engineering
· NACE 7219
Est. 2014
0 employees
Watchlist
Share
Sweden
/
Companies
/
Other research and experimental development on natural sciences and engineering
/
Emeriti Pharma AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
0M
1M
1M
1M
0M
2016
0M
2017
0M
2018
0M
2019
EBITDA
SEK millions
0M
0M
1M
1M
1M
-2M
2016
-3M
2017
0M
2018
0M
2019
Income statement
SEK thousands
Item
2016
2017
2018
2019
Revenue
60
1
0
0
Staff expenses
—
—
—
—
EBITDA
−2 359
−2 912
−361
180
Depreciation & amort.
−0
−0
−0
−0
EBIT
−2 359
−2 912
−361
180
Net financials
−3
−4
−6
−3
Profit before tax
−2 362
−2 916
−367
177
Tax
−0
−0
−0
−0
Net profit
−2 362
−2 916
−367
177
Balance sheet
SEK thousands
Item
2016
2017
2018
2019
Total assets
4 083
642
117
73
Equity
2 949
34
−333
73
Long-term debt
420
418
417
0
Short-term debt
713
189
33
0
Total debt
1 133
607
450
—
Financial ratios
5-year trend
EBITDA margin
18000000.0%
This company
15.8%
Market median
+113923951% vs market
2016
2019
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
2016
2019
Return on equity
242.5%
This company
18.4%
Market median
+1218% vs market
2016
2019
Net profit margin
17700000.0%
This company
8.1%
Market median
+218518419% vs market
2016
2019
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
2016
2019
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
2016
2019
Annual reports & filings
Annual report 2019
Filed via Bolagsverket / SCB · Period 2018-11-01 – 2019-10-31
View
PDF
Annual report 2018
Filed via Bolagsverket / SCB · Period 2017-11-01 – 2018-10-31
View
PDF
Annual report 2017
Filed via Bolagsverket / SCB · Period 2016-11-01 – 2017-10-31
View
PDF
Annual report 2016
Filed via Bolagsverket / SCB · Period 2015-11-01 – 2016-10-31
View
PDF
More on Emeriti Pharma AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
